20391 ⎘
Medicinal preparations containing organic active ingredients; Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom; Quinolines; Isoquinolines 2-Quinolinones, e.g. carbostyril
HETEROCYCLIC COMPOUNDS AND USES THEREOF
#2PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF RADIATION INDUCED TOXICITY
#3NAMPT MODULATORS, PREPARATIONS, AND USES THEREOF
#4TPK AGONIST AND METHOD FOR USING SAME TO TREAT NEURODEGENERATIVE DISEASES
#5LIQUID FORMULATIONS OF INDACATEROL
#6PLURALITY OF TASQUINIMOD PARTICLES AND USE THEREOF
#7PHARMACEUTICAL COMPOSITION FOR INHALATION FOR PREVENTING OR TREATING RESPIRATORY DISEASE
#8COMBINATION OF RADIATION/CHEMOTHERAPY, PD-1 INHIBITOR AND FATTY ACID SYNTHASE INHIBITOR
#9COMPOUND MEDICINE COMPOSITION FOR TREATING GLAUCOMA AND USE OF SAME
#10CYCLOALKYL CARBOXYLIC ACID DERIVATIVES AS INHIBITORS OF GLYCOGEN SYNTHASE 1 (GYS1) AND METHODS OF USE THEREOF
#11COMPOUNDS FOR TREATMENT A CORONAVIRUS INFECTION
#12METHODS AND COMPOSITIONS RELATING TO STEROID HORMONE RECEPTOR-DEPENDENT PROLIFERATIVE DISORDERS
#13THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKER
#14TREATMENT FOR GLOMERULAR DISEASES
#15COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS
#163,4-DIHYDROQUINOLIN-2(1H)-ONE COMPOUND
#17COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS
#18ALPHA 4 BETA 7 INTEGRIN MODULATORS AND USES THEREOF
#19COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDER
#20SPECIFIC TETRADENTATE COPPER CHELATORS AS ANTICANCER AGENTS
#21APPLICATION OF PHD2 INHIBITOR IN PREPARATION OF DRUGS FOR PREVENTION AND TREATMENT OF PLATELET THROMBUS
#22STABLE POLYMORPHIC COMPOSITIONS OF BREQUINAR SODIUM AND METHODS OF USE AND MANUFACTURE THEREOF
#23METHODS OF P21 SUPPRESSION FOR BONE REGENERATION AND HEALING
#24COMPOSITION FOR PREVENTING OR TREATING VALVULAR CALCIFICATION
#25METHODS AND COMPOSITIONS FOR MEASURING AND INHIBITING EXONUCLEASE ACTIVITY
#26COMPANION DIAGNOSTICS AND STRATEGIES FOR TREATMENT WITH AN ARYL HYDROCARBON RECEPTOR AGONIST COMPOUND
#27LIQUID FORMULATIONS OF INDACATEROL AND GLYCOPYRRONIUM
#28ALLOSTERIC STING MODULATORS AND METHODS OF USE
#29SMALL MOLECULES FOR INHIBITING CHEMOKINE ACTIVITY AND/OR CANCER CELLS GROWTH
#30POLYCYCLIC COMPOUND AND USE THEREOF
#31COMPOUNDS FOR USE IN THE TREATMENT OF DYSTROPHINOPATHIES
#32COMPOSITIONS OF AUTOPHAGY MODULATING AGENTS AND USES THEREOF
#33TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD
#34SMALL MOLECULE PIM AND MTOR KINASE INHIBITOR AND METHODS OF USE THEREOF
#35TREATMENT OF MULTIPLE SCHLEROSIS COMPRISING DHODH INHIBITORS
#36DIHYDROQUINOLINONES FOR MEDICAL TREATMENT
#37COMPOUNDS FOR TREATMENT OF CANCER
#38RXFP1 AGONISTS
#39USE OF GCN2 INHIBITORS IN TREATING CANCER
#40DESIDUSTAT PARTICLES AND COMPOSITIONS THEREOF
#41METHODS AND AGENTS FOR MODULATING THE IMMUNE RESPONSE
#42SULFONAMIDE OREXIN RECEPTOR AGONISTS AND USES THEREOF
#43FORMULATIONS FOR THE TREATMENT OF RESPIRATORY DISORDERS
#44INHIBITING INTRACELLULAR PATHOGENS
#45A QUINOLONE COMPOUND IN SOLID FORMS AND PROCESSES FOR THE PREPARATION THEREOF
#46SMALL MOLECULE COMPOUNDS TARGETING SRSF6 PROTEIN AND THEIR PREPARATION METHODS AND APPLICATIONS
#47IL4I1 INHIBITORS AND METHODS OF USE
#48A PLURALITY OF TASQUINIMOD PARTICLES AND USE THEREOF
#49A PHARMACEUTICAL PRODUCT CONTAINING TASQUINIMOD AND A METHOD FOR ASSESSING THE PURITY OF SAID PRODUCT
#501,2-DIHYDROQUINOLINE-2-ONES FOR THEIR USE IN THE TREATMENT OF LIMB-GIRDLE MUSCULAR DYSTROPHY
#51LONG-ACTING FORMULATIONS
#52NEURO-MESENCHYME UNITS CONTROL ILC2 AND OBESITY VIA A BRAIN-ADIPOSE CIRCUIT
#53METHODS AND COMPOSITIONS RELATING TO STEROID HORMONE RECEPTOR-DEPENDENT PROLIFERATIVE DISORDERS
#54KYNRENINE AND DERIVATIVES THEREOF FOR TREATING ATROPHIC SCARRING
#55COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE-ASSOCIATED INFLAMMATION AND DISORDER
#56Treatment of Multiple Sclerosis Comprising DHODH Inhibitors
#57LAQUINIMOD FORMULATION FOR OCULAR USE
#58TREATMENT OF SICKLE CELL ANAEMIA
#59ASSISTED LOADING OF HYDROPHOBIC MOLECULES INTO LIPOSOMES
#60COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT
#61LIQUID FORMULATIONS OF INDACATEROL
#62TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN THE TREATMENT OF MYELODYSPLASTIC SYNDROME
#63PHARMACEUTICAL COMPOSITION
#64PHARMACEUTICAL COMPOSITION
#65PHARMACEUTICAL COMPOSITION FOR TREATMENT OF AORTIC ANEURYSM
#66New use of (R)-B2-agonists in treatment of sepsis and acute respiratory distress syndrome
#67DISEASE MONITORING FROM INSURANCE CLAIMS DATA
#68CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS
#69SOLUTION FOR ORAL ADMINISTRATION
#70RECOMBINANT RHABDOVIRUS ENCODING FOR CCL21
#71METHODS FOR TREATING DISEASES MEDIATED BY GLUTATHIONE PEROXIDASE 4
#72TRUXILLIC ACID MONOESTER-DERIVATIVES AS SELECTIVE FABP5 INHIBITORS AND PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
#73Ocular surface drug retention agent, eye drop containing the same, and method for retention of ocular surface drug using the same and method for treating ocular disease
#74COMPOSITIONS AND METHODS FOR COMBINATORIAL DRUG DISCOVERY IN NANOLITER DROPLETS
#75Small molecule inhibitors of cancer stem cells and mesenchymal cancer types
#76COMPOUNDS AND METHODS OF MODULATING 17B-HYDROXYSTEROID DEHYDROGENASE TYPE 13
#77S100 PROTEINS AS NOVEL THERAPEUTIC TARGETS IN MYELOPROLIFERATIVE NEOPLASMS
#78METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
#79COMPOUNDS FOR TREATING OPHTHALMIC DISEASES AND DISORDERS
#80Tetrahydrobenzoazepinones and Related Analogs for Inhibiting YAP/TAZ-TEAD
#81TREATMENT FOR PSORIASIS AND SKIN INFLAMMATORY DISEASES
#82TREATMENT FOR THE INFLAMMATORY BOWEL DISEASE
#83Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
#84Dihydroquinolinones for medical treatment
#85SILVER SALT-CONTAINING OPHTHALMIC AQUEOUS COMPOSITION FILLED IN RESIN CONTAINER
#86SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME
#87Methods and compositions relating to steroid hormone receptor-dependent proliferative disorders
#88METHOD TO TREAT MANGANESE TOXICITY AND MANGANESE-INDUCED PARKINSONISM IN HUMANS
#89TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR USE IN COMBINATION THERAPY
#90Compounds for treatment of eye diseases associated with excessive vascularisation
#91Treatment of multiple sclerosis comprising DHODH inhibitors
#92COMPOUNDS FOR THE TREATMENT OF PARAMYXOVIRUS VIRAL INFECTIONS
#93TREATMENT OF DISEASES BY CONCURRENTLY ELICITING REMYELINATION EFFECTS AND IMMUNOMODULATORY EFFECTS USING SELECTIVE RXR AGONISTS
#94Use of R-enantiomer Beta2-agonists for prevent and treatment of pulmonary inflammation and inflammatory remodeling for reduced adverse effects
#95REBAMIPIDE FOR USE IN PREVENTION AND/OR TREATMENT OF ARTERIAL STIFFNESS
#96REBAMIPIDE FOR USE IN PREVENTION AND TREATMENT OF CROHN'S DISEASE
#97REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CANCER
#98REBAMIPIDE FOR USE IN PROPHYLAXIS AND TREATMENT OF CELIAC DISEASE
#99METHODS AND FORMULATIONS FOR TREATING VISION DISORDERS
#100INHALABLE SUSTAINED RELEASE COMPOSITION OF BRONCHODILATOR FOR USE IN TREATING PULMONARY DISEASE
#101REBAMIPIDE FOR USE IN PREVENTION AND/OR TREATMENT OF SYNUCLEINOPATHIES
#102Methods for preventing and treating or diagnosing coronavirus infection
#103Pharmaceutical Inhalation Aerosol and Preparation Method Therefor
#104Parasite therapy
#105PHARMACEUTICAL COMPOSITION FOR TREATING AORTIC ANEURYSM
#106Autoimmune disorder treatment using RXR agonists
#107Therapeutic material with low pH and low toxicity active against at least one pathogen for addressing patients with respiratory illnesses
#108PHARMACEUTICAL COMPOSITION
#109COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING BETA-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA
#110Autoimmune disorder treatment using RXR agonists
#111NT5C2 INHIBITORS FOR THE TREATMENT OF CHEMOTHERAPY-RESISTANT ACUTE LYMPHOBLASTIC LEUKEMIA
#112COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN
#113Liquid formulations of indacaterol
#114Method and system for reducing the likelihood of a porphyromonas gingivalis infection in a human being
#115BET INHIBITORS FOR MODULATING DUX4 EXPRESSION IN FSHD
#116Small Molecule Analogs Of The Protein E4ORF1 In The Treatment And Prevention Of Metabolic Disorders
#117Methods for preventing and treating or diagnosing coronavirus infection
#118Therapies That Target Autoimmunity For Treating Glaucoma And Optic Neuropathy
#119PHARMACEUTICAL COMPOSITION FOR TREATMENT OF AORTIC ANEURYSM
#120Small molecules for inhibiting chemokine activity and/or cancer cells growth
#121METHODS OF TREATING CANCER WITH FARNESYLTRANSFERASE INHIBITORS
#122INHIBITORS AND ANTAGONISTS OF GPR84 FOR THE TREATMENT OF ENDOMETRIOSIS
#123Pharmaceutical composition
#124COMPOSITION FOR PREVENTING OR TREATING SJOGREN'S SYNDROME
#125New use of R-enantiomer of adrenergic beta 2 receptor agonists for treatment of inflammatory bowel disease and its extra intestinal manifestations
#126TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD
#127PHARMACEUTICAL FORMULATION CONTAINING GLYCOPYRROLATE AND INDACATEROL MALEATE
#128INHALABLE MEDICAMENTS
#129OPHTHALMIC PREPARATIONS OF MUSCARINIC AGONIST AND METHODS OF USE
#130Methods of treatment for disease from coronavirus exposure
#131Methods and compositions for treatment of glaucoma and related conditions
#132Isolated nanosheet and production method thereof
#133Compounds for treatment of eye diseases associated with excessive vascularisation
#134Pharmaceutical composition
#135Pharmaceutical composition
#136Pharmaceutical composition
#137Pharmaceutical Compositions
#138CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS
#139COMBINATIONS INCLUDING BETA-ADRENORECEPTOR AGONISTS FOR TREATMENT OF PARKINSON`S DISEASE AND MOVEMENT DISORDERS
#140Stable polymorphic compositions of brequinar sodium and methods of use and manufacture thereof
#141METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
#142METHODS FOR IMPROVING NEUROLOGICAL DISEASES AND DISORDERS
#143COMPOSITIONS AND METHODS FOR THE TREATMENT OF CHRONIC PAIN
#144Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
#145METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE
#146PHARMACEUTICAL COMPOSITIONS FOR TREATING BREAST CANCERS AND METHODS OF USES THEREOF
#147ARYL HYDROCARBON RECEPTOR ANTAGONISTS AND METHODS OF USE
#148Small molecule inhibitors of cancer stem cells and mesenchymal cancer types
#149Tissue repair
#150Methods of treating exercise-induced pulmonary hemorrhage
#151Treatment of skeletal-related events for breast cancer patients
#152Autoimmune disorder treatment using RXR agonists
#153Autoimmune disorder treatment using RXR agonists
#154TREATMENT AGENT AND PHARMACEUTICAL COMPOSITION FOR GLIOMA
#155COMPOSITIONS AND METHODS THAT PROMOTE HYPOXIA OR THE HYPOXIA RESPONSE FOR TREATMENT AND PREVENTION OF MITOCHONDRIAL DYSFUNCTION AND OXIDATIVE STRESS DISORDERS
#156THERAPEUTIC AGENT FOR GLAUCOMA COMPRISING FP AGONIST AND ß BLOCKER
#157SYNERGISTIC DRUG COMBINATIONS PREDICTED FROM GENOMIC FEATURES AND SINGLE-AGENT RESPONSE PROFILES
#158Compounds for treatment of PD-L1 diseases
#159NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE
#160METHOD OF TREATING BIPOLAR I AND II DISORDERS
#161INHALABLE FORMULATION OF A SOLUTION CONTAINING INDACATEROL MALEATE AND GLYCOPYRRONIUM BROMIDE
#162Methods of treating radiation induced gastrointestinal syndrome (RIGS) and related disease states using YEL002/BCN057
#163Compositions and methods for combinatorial drug discovery in nanoliter droplets
#164Methods and compositions for treatment of muscle wasting, muscle weakness, and/or cachexia
#165PD-1 related cancer therapy
#166CURE FOR ALZHEIMER'S DISEASE
#167Method for the treatment of valvular heart disease comprising administering a composition comprising sarpogrelate
#168CARBOSTYRIL DERIVATIVES AND MOOD STABILIZERS FOR TREATING MOOD DISORDERS
#169Methods of treating cancer with farnesyltransferase inhibitors
#170Recombinant rhabdovirus encoding for CCL21
#171NEBULIZATION COMPOSITION COMPRISING TIOTROPIUM AND INDACATEROL
#172Pharmaceutical composition for treatment of aortic aneurysm
#173Use Of Cholesterol For Promoting Survival And Proliferation Of Primary Medulloblastoma Cells
#174TREATMENT OF DISEASES BY CONCURRENTLY ELICITING REMYELINATION EFFECTS AND IMMUNOMODULATORY EFFECTS USING SELECTIVE RXR AGONISTS
#175FORMULATION COMPRISING GLYCOPYRROLATE, METHOD AND APPARATUS
#176Autoimmune disorder treatment using RXR agonists
#177AUTOIMMUNE DISORDER TREATMENT USING RXR AGONISTS
#178CRYSTALLINE MICROPARTICLES OF A BETA-AGONIST COATED WITH A FATTY ACID
#179COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT
#180Methods and compositions for the inhibition of PIN1
#181METHOD OF TREATING BIPOLAR I AND II DISORDERS
#182Pharmaceutical solution formulations for pressurized metered dose inhalers
#183Method for making a micronized dry powder formulation of glycopyrrolate and magnesium stearate
#184Parasite therapy
#185METHODS OF TREATING GLIOBLASTOMA MULTIFORME USING IBUDILAST
#186Lactam compound, preparation method and use thereof
#187Pharmaceutical composition
#188Pharmaceutical composition
#189NRF2 Screening Assays and Related Methods and Compositions
#190ALKYL DIHYDROQUINOLINE SULFONAMIDE COMPOUNDS
#191METHODS OF TREATING RADIATION INDUCED GASTROINTESTINAL SYNDROME (RIGS) AND RELATED DISEASE STATES USING YEL002/BCN057
#192Pharmaceutical composition
#193Compositions and methods for the treatment of chronic pain
#194Small molecules for inhibiting chemokine activity and/or cancer cells growth
#195Molecular adjuvants for enhanced cytosolic delivery of active agents
#196Antitumor agent and bromodomain inhibitor
#197Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
#198Pharmaceutical composition
#199IDENTIFICATION OF NOVEL LOCI IN ASTHMA AND METHODS OF USE THEREOF FOR THE DIAGNOSIS AND TREATMENT OF ASTHMA
#200MDR-reversing 8-hydroxy-quinoline derivatives
#201PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
#202K-RAS MUTATIONS AND ANTAGONISTS
#203Non-invasive method of evaluating breast cancers for selective androgen receptor modulator (SARM) therapy
#204Autoimmune disorder treatment using RXR agonists
#205COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
#206Method of treating ER mutant expressing breast cancers with selective androgen receptor modulators (SARMs)
#207DISEASE MONITORING FROM INSURANCE CLAIMS DATA
#208COMBINATION THERAPY FOR TREATMENT OF MULTIPLE SCLEROSIS
#209Nitrogen-containing heterocyclic compound
#210Mutant IDH1 inhibitors useful for treating cancer
#211PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF
#212Inhalation atomizer comprising a blocking function and a counter
#213Methods of treating symptoms of gastroparesis using velusetrag
#214Compositions and methods that promote hypoxia or the hypoxia response for treatment and prevention of mitochondrial dysfunction and oxidative stress disorders
#215COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
#216Alkyl dihydroquinoline sulfonamide compounds
#217Alkynyl dihydroquinoline sulfonamide compounds
#218Methods and compositions for treatment of demyelinating diseases
#219QUINOLONE CHALCONE COMPOUNDS AND USES THEREOF
#220Pyridinyl quinolinone derivatives as mutant-isocitrate dehydrogenase inhibitors
#221Process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
#222USE OF LAQUINIMOD TO DELAY HUNTINGTON'S DISEASE PROGRESSION
#223Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect
#224Ophthalmic composition comprising rebamipide and method for preparing the same
#225Autoimmune disorder treatment using RXR agonists
#226NRF2 Screening Assays and Related Methods and Compositions
#227COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
#228QUINOLINE DERIVATIVES FOR USE IN TREATING LEUKODYSTROPHY AND TREATMENT METHOD
#229Use of ceranib-2 in the treatment of lung cancer
#230Combination therapies for treatment of spinal muscular atrophy
#231NANOPARTICLES FOR SUSTAINED OPHTHALMIC DRUG DELIVERY AND METHODS OF USE
#232Methods of treating glioblastoma multiforme using ibudilast
#233PHARMACEUTICAL COMPOSITIONS AND ADMINISTRATIONS THEREOF
#234TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD
#235Treatment of Glaucoma Using Laquinimod
#2365-CHLORO-4-HYDROXY-1-METHYL-2-OXO-N-PHENYL-1,2-DIHYDROQUINOLINE-3-CARBOXAMIDE, SALTS AND USES THEREOF
#237COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
#238Tetrahydrocarbazole Inhibitors Of SIRT1 Receptors
#239Autoimmune disorder treatment using RXR agonists
#240PYRIDINYL QUINOLINONE DERIVATIVES AS MUTANT-ISOCITRATE DEHYDROGENASE INHIBITORS
#241Combinations of Glycopyrrolate and Beta2 Adrenoceptor Agonists
#242Treatment of ocular inflammatory diseases using laquinimod
#243TREATMENT OF PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
#244Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate
#245COMBINATION OF TASQUINIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND A PD-1 AND/OR PD-L1 INHIBITOR, FOR USE AS A MEDICAMENT
#246TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
#247TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND A STATIN
#248Preparation and anti-HSV-1 application of quinolinone derivatives
#249Alkaloids and their preparation and application as anti-HSV-1 agents
#250TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD
#251Treatment of Glaucoma Using Laquinimod
#252TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD
#253Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And Fingolimod
#254Pharmaceutical compositions
#255TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD
#256TREATMENT OF MULTIPLE SCLEROSIS WITH COMBINATION OF LAQUINIMOD AND FINGOLIMOD
#257Method for reducing, inhibiting, and eliminating inflammation and pain with transdermal delivery of iron chelator composition
#258Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate
#259COMBINATION OF LAQUINIMOD AND PRIDOPIDINE FOR TREATING NEURODEGENERATIVE DISORDERS, IN PARTICULAR HUNTINGTON'S DISEASE
#260Quinoline carboxamides for use in the treatment of leukemia
#261Compounds for inhibiting drug-resistant strains of HIV-1 integrase
#262Methods and compositions for the inhibition of Pin1
#263Combinations comprising siponimod and laquinimod for the treatment of multiple sclerosis
#264Laquinimod Combination Therapy For Treatment Of Multiple Sclerosis
#265Perk activator for the treatment of neurodegenerative diseases
#266QUINOLONES AS INHIBITORS OF CLASS IV BROMODOMAIN PROTEINS
#267USE OF LAQUINIMOD FOR TREATING CROHN'S DISEASE PATIENTS WHO FAILED FIRST-LINE ANTI-TNF THERAPY
#268Compounds for the treatment of paramyxovirus viral infections
#269Taurine compositions suitable for inhalation
#270TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD
#271Treatment of Glaucoma Using Laquinimod
#272TREATMENT OF LUPUS NEPHRITIS USING LAQUINIMOD
#273Formulation comprising glycopyrrolate, method and apparatus
#274Ataxia therapeutic compositions and methods
#275TREATMENT OF BDNF-RELATED DISORDERS USING LAQUINIMOD
#276Combination therapies for treatment of spinal muscular atrophy
#277TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD
#278Treatment of Multiple Sclerosis With Combination of Laquinimod and Dimethyl Fumarate
#279Treatment Of Neurodegenerative Diseases With Combination Of Laquinimod And Fingolimod
#280Methods of treating exercise-induced pulmonary hemorrhage
#281Method of treating HER2-positive breast cancers with selective androgen receptor modulators (SARMS)
#282Heterocyclic GSK-3 allosteric modulators
#283Tetrahydrocarbazole inhibitors of SIRT1 receptors
#284BROMODOMAIN AND EXTRA-TERMINAL PROTEIN INHIBITOR COMBINATION THERAPY
#285SELECTIVE SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS AND COMBINATION THERAPY THEREWITH
#286Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
#287LAQUINIMOD FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) PATIENTS WITH A HIGH DISABILITY STATUS
#288TREATMENT OF CROHN'S DISEASE WITH LAQUINIMOD
#289Treatment of Glaucoma Using Laquinimod
#290TREATMENT OF MULTIPLE SCLEROSIS WITH LAQUINIMOD
#291Compounds having muscarinic receptor antagonist and BETA2 adrenergic receptor agonist activity
#292Pharmaceutical Composition Comprising a Beta-2-Agonist and Anticholinergic Agent
#293USE OF LAQUINIMOD TO DELAY HUNTINGTON'S DISEASE PROGRESSION
#294Method and system for reducing the likelihood of a spirochetes infection in a human being
#295Compounds for treating ophthalmic diseases and disorders
#296TRANSMUCOSAL DELIVERY OF LAQUINIMOD BY ORAL PATCHES
#297N-ETHYL-N-PHENYL-1,2-DIHYDRO-4,5-DI-HYDROXY-1-METHYL-2-OXO-3-QUINOLINECARBOXAMIDE, PREPARATION AND USES THEREOF
#298Pharmaceutical solution formulations for pressurised metered dose inhalers
#299Autoimmune disorder treatment using RXR agonists
#300Heterocyclic compound